Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365017 | 0.84 | KDM5A (0.37) | KDM5AGABRA1GABRB1GABRB2KDM4E | |
| SCHEMBL17802285 | 0.82 | KDM5A (0.36) | KDM5AGABRA1GABRB1GABRB2KDM4E | |
| SCHEMBL10027186 | 0.79 | CHEK1 (0.32) | KDM5AGABRA1GABRB2KDM4EALDH1A1 | |
| SCHEMBL17808906 | 0.79 | KDM5A (0.34) | KDM5ALMNA | |
| SCHEMBL19365016 | 0.79 | KDM5A (0.34) | KDM5A | |
| SCHEMBL17802271 | 0.78 | BTK (0.34) | KDM5AKDM4EALDH1A1GAALMNA | |
| SCHEMBL17802259 | 0.78 | ALDH1A1 (0.36) | KDM5AKDM4EALDH1A1GAALMNA | |
| SCHEMBL17808751 | 0.78 | RPS6KA3 (0.37) | KDM5AALDH1A1CYP3A4TP53 | |
| SCHEMBL24344674 | 0.77 | KDM5A (0.33) | KDM5AKDM4ETP53 | |
| SCHEMBL17808905 | 0.77 | KDM5B (0.38) | KDM5AKDM4EALDH1A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-05-18 | — | — | US | disclosed |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-11-21 | — | — | US | disclosed |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-05-14 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| EP-2044026-B1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM5A 3207/4885GABRA1 316/4885GABRB1 362/4885 |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | KDM5A 2270/4885GABRA1 1553/4885GABRB1 971/4885 |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM5A 3207/4885GABRA1 316/4885GABRB1 362/4885 |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM5A 4122/4885GABRA1 3103/4885GABRB1 2435/4885 |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM5A 3207/4885GABRA1 316/4885GABRB1 362/4885 |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM5A 3207/4885GABRA1 316/4885GABRB1 362/4885 |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM5A 3207/4885GABRA1 316/4885GABRB1 362/4885 |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM5A 4122/4885GABRA1 3103/4885GABRB1 2435/4885 |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM5A 3207/4885GABRA1 316/4885GABRB1 362/4885 |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM5A 4122/4885GABRA1 3103/4885GABRB1 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.